Ocata Therapeutics Inc fka OCAT

[rocky301]

SpleniusCapitis,

To my knowledge all patients ACT has treated to date for SMD/AMD trials are on the immunosuppression regimen.
ACT has no trial for hemangioblast at this time so I am not sure what that has to do with current trials underway?

Here is a clip from the Lancet Publication on ACT's first two patients..

" The immunosuppression regimen included low-dose tacrolimus (target blood concentrations 3–7 ng/mL) and mycophenolate mofetil (ranging from 0·25 to 2·00 g orally per day) a week before the surgical procedure and continued for 6 weeks. At week 6, the regimen calls for discontinuation of tacrolimus and a continuation of mycophenolate mofetil for an additional 6 weeks."
http://download.thelancet.com/flatcontentassets/pdfs/S0140673612600282.pdf

A recent article on the UK patient, Marcus Hilton,

"Hilton is taking the drugs as a precaution and hates the side effects, but hopes he will be able to stop."
http://www.guardian.co.uk/science/2012/jun/04/stem-cell-first-human-trials